{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:43:47Z","timestamp":1793403827285,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences, Asan Medical Center","doi-asserted-by":"publisher","award":["2023IP0085"],"award-info":[{"award-number":["2023IP0085"]}],"id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005006","name":"Asan Institute for Life Sciences, Asan Medical Center","doi-asserted-by":"publisher","award":["2024IF0003"],"award-info":[{"award-number":["2024IF0003"]}],"id":[{"id":"10.13039\/501100005006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["RS-2018-KH049509"],"award-info":[{"award-number":["RS-2018-KH049509"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04168-6","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T08:38:27Z","timestamp":1767429507000},"page":"2273-2285","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical utility of longitudinal circulating tumor DNA analysis in metastatic colorectal cancer patients receiving palliative chemotherapy"],"prefix":"10.1007","volume":"28","author":[{"given":"Chung Ryul","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha Ra","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Min","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5672-0072","authenticated-orcid":false,"given":"Yong Sang","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"issue":"3","key":"4168_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"4168_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.102882","volume":"147","author":"E Rassy","year":"2020","unstructured":"Rassy E, Parent P, Lefort F, Boussios S, Baciarello G, Pavlidis N. New rising entities in cancer of unknown primary: is there a real therapeutic benefit? Crit Rev Oncol Hematol. 2020;147:102882.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"4168_CR3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1001\/jamaoncol.2023.5098","volume":"10","author":"J Nors","year":"2024","unstructured":"Nors J, Iversen LH, Erichsen R, Gotschalck KA, Andersen CL. Incidence of recurrence and time to recurrence in stage I to III colorectal cancer: a nationwide Danish cohort study. JAMA Oncol. 2024;10(1):54\u201362.","journal-title":"JAMA Oncol"},{"key":"4168_CR4","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program. Recent trends in SEER age-adjusted incidence rates, 2000\u20132022. In: SEER Cancer Stat Facts: Colorectal Cancer. National Cancer Institute. https:\/\/seer.cancer.gov\/statfacts\/html\/colorect.html."},{"key":"4168_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12091534","author":"M Osseis","year":"2022","unstructured":"Osseis M, Nehmeh WA, Rassy N, Derienne J, Noun R, Salloum C, et al. Surgery for T4 colorectal cancer in older patients: determinants of outcomes. J Pers Med. 2022. https:\/\/doi.org\/10.3390\/jpm12091534.","journal-title":"J Pers Med"},{"key":"4168_CR6","unstructured":"NCCN Guidelines. Colon cancer, Version 5. 2024."},{"issue":"1","key":"4168_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes A, Adam R, Rosell\u00f3 S, Arnold D, Normanno N, Ta\u00efeb J, et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10\u201332.","journal-title":"Ann Oncol"},{"issue":"23","key":"4168_CR8","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207\u201318.","journal-title":"N Engl J Med"},{"issue":"21","key":"4168_CR9","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1056\/NEJMoa2402141","volume":"391","author":"T Andre","year":"2024","unstructured":"Andre T, Elez E, Van Cutsem E, Jensen LH, Bennouna J, Mendez G, et al. Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer. N Engl J Med. 2024;391(21):2014\u201326.","journal-title":"N Engl J Med"},{"issue":"1","key":"4168_CR10","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1373\/clinchem.2014.222679","volume":"61","author":"E Heitzer","year":"2015","unstructured":"Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem. 2015;61(1):112\u201323.","journal-title":"Clin Chem"},{"issue":"4","key":"4168_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","volume":"17","author":"JCM Wan","year":"2017","unstructured":"Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223\u201338.","journal-title":"Nat Rev Cancer"},{"issue":"24","key":"4168_CR12","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1200\/JCO.21.02615","volume":"40","author":"M Malla","year":"2022","unstructured":"Malla M, Loree JM, Kasi PM, Parikh AR. Using circulating tumor DNA in colorectal cancer: current and evolving practices. J Clin Oncol. 2022;40(24):2846\u201357.","journal-title":"J Clin Oncol"},{"issue":"22","key":"4168_CR13","doi-asserted-by":"publisher","first-page":"4530","DOI":"10.1158\/1078-0432.CCR-23-0079","volume":"29","author":"G Patelli","year":"2023","unstructured":"Patelli G, Mauri G, Tosi F, Amatu A, Bencardino K, Bonazzina E, et al. Circulating tumor DNA to drive treatment in metastatic colorectal cancer. Clin Cancer Res. 2023;29(22):4530\u20139.","journal-title":"Clin Cancer Res"},{"issue":"224","key":"4168_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra224.","journal-title":"Sci Transl Med"},{"issue":"12","key":"4168_CR15","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41591-020-1063-5","volume":"26","author":"Y Nakamura","year":"2020","unstructured":"Nakamura Y, Taniguchi H, Ikeda M, Bando H, Kato K, Morizane C, et al. Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat Med. 2020;26(12):1859\u201364.","journal-title":"Nat Med"},{"issue":"1","key":"4168_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41591-022-02115-4","volume":"29","author":"D Kotani","year":"2023","unstructured":"Kotani D, Oki E, Nakamura Y, Yukami H, Mishima S, Bando H, et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med. 2023;29(1):127\u201334.","journal-title":"Nat Med"},{"issue":"24","key":"4168_CR17","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","volume":"386","author":"J Tie","year":"2022","unstructured":"Tie J, Cohen JD, Lahouel K, Lo SN, Wang Y, Kosmider S, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022;386(24):2261\u201372.","journal-title":"N Engl J Med"},{"issue":"11","key":"4168_CR18","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1158\/2159-8290.CD-14-0462","volume":"4","author":"S Misale","year":"2014","unstructured":"Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Bardelli A. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov. 2014;4(11):1269\u201380.","journal-title":"Cancer Discov"},{"issue":"2","key":"4168_CR19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1158\/2159-8290.CD-15-1283","volume":"6","author":"M Russo","year":"2016","unstructured":"Russo M, Siravegna G, Blaszkowsky LS, Corti G, Crisafulli G, Ahronian LG, et al. Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. Cancer Discov. 2016;6(2):147\u201353.","journal-title":"Cancer Discov"},{"key":"4168_CR20","doi-asserted-by":"publisher","first-page":"13665","DOI":"10.1038\/ncomms13665","volume":"7","author":"BO Van Emburgh","year":"2016","unstructured":"Van Emburgh BO, Arena S, Siravegna G, Lazzari L, Crisafulli G, Corti G, et al. Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nat Commun. 2016;7:13665.","journal-title":"Nat Commun"},{"issue":"10","key":"4168_CR21","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1158\/1078-0432.CCR-16-1863","volume":"23","author":"F Pietrantonio","year":"2017","unstructured":"Pietrantonio F, Vernieri C, Siravegna G, Mennitto A, Berenato R, Perrone F, et al. Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer. Clin Cancer Res. 2017;23(10):2414\u201322.","journal-title":"Clin Cancer Res"},{"issue":"7404","key":"4168_CR22","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/nature11156","volume":"486","author":"S Misale","year":"2012","unstructured":"Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486(7404):532\u20136.","journal-title":"Nature"},{"issue":"14","key":"4168_CR23","doi-asserted-by":"publisher","first-page":"3775","DOI":"10.1158\/1078-0432.CCR-13-2181","volume":"20","author":"T Troiani","year":"2014","unstructured":"Troiani T, Napolitano S, Vitagliano D, Morgillo F, Capasso A, Sforza V, et al. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK\/ERK pathway activation and can be overcome by combined MEK\/EGFR inhibition. Clin Cancer Res. 2014;20(14):3775\u201386.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"4168_CR24","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1158\/1078-0432.CCR-23-4005","volume":"30","author":"E Harrold","year":"2024","unstructured":"Harrold E, Keane F, Walch H, Chou JF, Sinopoli J, Palladino S, et al. Molecular and clinical determinants of acquired resistance and treatment duration for targeted therapies in colorectal cancer. Clin Cancer Res. 2024;30(12):2672\u201383.","journal-title":"Clin Cancer Res"},{"key":"4168_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13082038","author":"I Kyrochristou","year":"2025","unstructured":"Kyrochristou I, Lianos GD, Kyrochristou GD, Anagnostopoulos G, Bali C, Boussios S, et al. Agnostic biomarkers and molecular signatures in colorectal cancer-guiding chemotherapy and predicting response. Biomedicines. 2025. https:\/\/doi.org\/10.3390\/biomedicines13082038.","journal-title":"Biomedicines"},{"key":"4168_CR26","doi-asserted-by":"publisher","first-page":"15617","DOI":"10.1038\/ncomms15617","volume":"8","author":"M Ali","year":"2017","unstructured":"Ali M, Kaltenbrun E, Anderson GR, Stephens SJ, Arena S, Bardelli A, et al. Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance. Nat Commun. 2017;8:15617.","journal-title":"Nat Commun"},{"issue":"8","key":"4168_CR27","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1038\/s41591-022-01886-0","volume":"28","author":"A Sartore-Bianchi","year":"2022","unstructured":"Sartore-Bianchi A, Pietrantonio F, Lonardi S, Mussolin B, Rua F, Crisafulli G, et al. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Nat Med. 2022;28(8):1612\u20138.","journal-title":"Nat Med"},{"key":"4168_CR28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3389\/fonc.2020.00221","volume":"10","author":"Y Haibe","year":"2020","unstructured":"Haibe Y, Kreidieh M, El Hajj H, Khalifeh I, Mukherji D, Temraz S, et al. Resistance mechanisms to anti-angiogenic therapies in cancer. Front Oncol. 2020;10:221.","journal-title":"Front Oncol"},{"issue":"1","key":"4168_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","volume":"14","author":"J Bennouna","year":"2013","unstructured":"Bennouna J, Sastre J, Arnold D, \u00d6sterlund P, Greil R, Van Cutsem E, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14(1):29\u201337.","journal-title":"Lancet Oncol"},{"issue":"33","key":"4168_CR30","doi-asserted-by":"publisher","first-page":"5326","DOI":"10.1200\/JCO.2008.16.3212","volume":"26","author":"A Grothey","year":"2008","unstructured":"Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol. 2008;26(33):5326\u201334.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4168_CR31","doi-asserted-by":"publisher","first-page":"20252","DOI":"10.1038\/s41598-024-70887-5","volume":"14","author":"TR Yoo","year":"2024","unstructured":"Yoo TR, Lee JY, Park H, Cho WK, Jeon S, Jun HR, et al. Longitudinal dynamics of circulating tumor DNA for treatment monitoring in patients with breast cancer recurrence. Sci Rep. 2024;14(1):20252.","journal-title":"Sci Rep"},{"issue":"6","key":"4168_CR32","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1093\/annonc\/mdx112","volume":"28","author":"J Grasselli","year":"2017","unstructured":"Grasselli J, Elez E, Carat\u00f9 G, Matito J, Santos C, Macarulla T, et al. Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol. 2017;28(6):1294\u2013301.","journal-title":"Ann Oncol"},{"issue":"9","key":"4168_CR33","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1158\/1078-0432.CCR-20-3677","volume":"27","author":"Y Kagawa","year":"2021","unstructured":"Kagawa Y, Elez E, Garc\u00eda-Foncillas J, Bando H, Taniguchi H, Vivancos A, et al. Combined analysis of concordance between liquid and tumor tissue biopsies for RAS mutations in colorectal cancer with a single metastasis site: the METABEAM study. Clin Cancer Res. 2021;27(9):2515\u201322.","journal-title":"Clin Cancer Res"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04168-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04168-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04168-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:32:17Z","timestamp":1779204737000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04168-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["4168"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04168-6","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,3]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}